Open access
97
Views
28
CrossRef citations to date
0
Altmetric
Original Research
Indacaterol/glycopyrronium versus salmeterol/fluticasone in Asian patients with COPD at a high risk of exacerbations: results from the FLAME study
Jadwiga A Wedzicha1 National Heart and Lung Institute, Imperial College London, London, UKCorrespondence[email protected]
, Nanshan Zhong2 State Key Laboratory of Respiratory Disease, National Clinical Research Center of Respiratory Disease, Guangzhou Institute of Respiratory Disease, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, People’s Republic of China
, Masakazu Ichinose3 Department of Respiratory Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan
, Michael Humphries4 Beijing Novartis Pharma Co. Ltd., Shanghai, People’s Republic of China
, Robert Fogel5 Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA
, Chau Thach5 Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA
, Francesco Patalano6 Novartis Pharma AG, Basel, Switzerland
& Donald Banerji5 Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA
show all
Pages 339-349
|
Published online: 19 Jan 2017
Reprints and Permissions
Permission is granted subject to the terms of the License under which the work was published. Permission will be required if your reuse is not covered by the terms of the License.
To request a reprint or commercial or derivative permissions for this article, please click on the relevant link below.
For more information please visit our Permissions help page.
Related research
People also read lists articles that other readers of this article have read.
Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.
Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.